Wow, this is appearing everywhere, so much going on. This is...

Wow, this is appearing everywhere, so much going on. This is certainly the transformational year as far as exposure goes. It seems everybody wants to be associated with Painchek. The revenue has to be increasing, the trials are all showing merit and making it harder and harder not to use it. Converting all this into revenue will no doubt lead to a huge uptick in the next few quarterlies. Partners are coupling up in the US ready for 2024.
Wales pilot progressing nicely, implementation continuing is NZ, Australia, & UK. Japan and Singapore have been quiet thus far but any news will be good news as this is also a huge market. I’m not sure we currently have the resources to expand further for now, but I’m only speculating. Managing our focus on established markets may be the theme until revenue equals core costs. Then expansion will be easier also as it will be an established medical device within the APAC region, and growing in Europe. It will almost sell itself by then.
Great job by Management & Team.
cheers